{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:03:54Z","timestamp":1784099034920,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Extracorporeal membrane oxygenation (ECMO) in patients following intracerebral hemorrhage (ICH) poses a critical dilemma between circuit thrombosis and catastrophic rebleeding. While nafamostat mesylate (NM) has been increasingly explored for ECMO anticoagulation in patients with ICH, it is conventionally administered as a systemic anticoagulant with high activated partial thromboplastin time (aPTT) targets, which still carries significant bleeding risks. Moreover, whether NM can achieve effective regional anticoagulation in venovenous (VV) ECMO remains highly controversial. Here, we present a post-ICH patient with severe ARDS who required VV-ECMO. Due to suspected rebleeding, anticoagulation was transitioned from heparin to an anticoagulant-free strategy, which subsequently led to significant oxygenator thrombosis. To navigate this crisis, NM was initiated with an ultra-low systemic target, but it initially failed to establish a regional anticoagulant effect when infused at the conventional pre-membrane, post-pump site. Crucially, relocating the NM infusion to the pre-pump position successfully established a significant circuit-to-systemic aPTT gradient. This technical optimization enabled effective circuit anticoagulation while minimizing systemic bleeding risk, allowing for successful ECMO weaning without bleeding complications. This dynamic intra-patient observation highlights the potential impact of infusion site on coagulation outcomes. We hypothesize that harnessing the centrifugal pump\u2019s high-shear turbulence for homogenous drug mixing might serve as a crucial prerequisite for achieving regional anticoagulation in VV-ECMO. These findings bridge the gap between theoretical pharmacology and practical circuit engineering, offering a practical preliminary reference for the future anticoagulant management of similar high-bleeding-risk patients on ECMO.<\/jats:p>","DOI":"10.3389\/fmed.2026.1840332","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:05:12Z","timestamp":1784095512000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Navigating the bleeding-thrombosis paradox: regional nafamostat anticoagulation in a post-intracerebral hemorrhage patient on VV-ECMO"],"prefix":"10.3389","volume":"13","author":[{"given":"Shujia","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangqiong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longxiang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s10072-023-07269-8","article-title":"Prevalence, predictors, and outcomes of acute respiratory distress syndrome in severe stroke","volume":"45","author":"Wang","year":"2024","journal-title":"Neurol Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3389\/fneur.2018.00548","article-title":"Incidence, outcome, and predictors of intracranial hemorrhage in adult patients on extracorporeal membrane oxygenation: a systematic and narrative review","volume":"9","author":"Fletcher-Sandersj\u00f6\u00f6","year":"2018","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1111\/aor.14276","article-title":"Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: a systematic review","volume":"46","author":"Sanfilippo","year":"2022","journal-title":"Artif Organs"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13054-025-05813-w","article-title":"Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis","volume":"30","author":"Liu","year":"2025","journal-title":"Crit Care"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.3346\/jkms.2025.40.e233","article-title":"Clinical outcomes of extracorporeal membrane oxygenation use in patients with intracranial hemorrhage","volume":"40","author":"Gu","year":"2025","journal-title":"J Korean Med Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.athoracsur.2016.01.044","article-title":"Anticoagulation during extracorporeal membrane oxygenation; Nafamostat Mesilate versus heparin","volume":"102","author":"Lim","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4266\/acc.2021.01312","article-title":"The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation","volume":"37","author":"Lee","year":"2022","journal-title":"Acute Crit Care"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5301\/ijao.5000451","article-title":"Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation","volume":"38","author":"Park","year":"2015","journal-title":"Int J Artif Organs"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1541131","DOI":"10.3389\/fphar.2025.1541131","article-title":"Pharmacokinetic and pharmacodynamic analyses of nafamostat in ECMO patients: comparing central vein and ECMO machine samples","volume":"16","author":"Lee","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40635-023-00525-3","article-title":"Reduced anticoagulation strategy is associated with a lower incidence of intracerebral hemorrhage in COVID-19 patients on extracorporeal membrane oxygenation","volume":"11","author":"Hofmaenner","year":"2023","journal-title":"Intensive Care Med Exp"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e01491","DOI":"10.1213\/XAA.0000000000001491","article-title":"Rocuronium-induced dilated nonreactive pupils in a patient with coronavirus disease 2019: a case report","volume":"15","author":"Rodrigues","year":"2021","journal-title":"AANA J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/MAT.0000000000001652","article-title":"2021 ELSO adult and pediatric anticoagulation guidelines","volume":"68","author":"McMichael","year":"2022","journal-title":"ASAIO J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0267659118766435","article-title":"Intracranial hemorrhage in adults on ECMO","volume":"33","author":"Cavayas","year":"2018","journal-title":"Perfusion"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/BF03018658","article-title":"In vitro relationship between the blood nafamostat concentration and activated coagulation time","volume":"50","author":"Iwama","year":"2003","journal-title":"Can J Anesth Can Anesth"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12876-022-02345-3","article-title":"The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis","volume":"22","author":"Kim","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12185-020-03030-5","article-title":"Diversity of disseminated intravascular coagulation and selection of appropriate treatments","volume":"113","author":"Asakura","year":"2021","journal-title":"Int J Hematol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12185-018-02567-w","article-title":"Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies","volume":"109","author":"Minakata","year":"2019","journal-title":"Int J Hematol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.19842\/j.cnki.issn.0253-9934.2024.03.001","article-title":"Expert consensus on application of nafamostat mesilate in anticoagulation for blood purification","volume":"47","year":"2024","journal-title":"Shanghai Med J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.5414\/CNP59458","article-title":"Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient","volume":"59","author":"Takahashi","year":"2003","journal-title":"Clin Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1002\/ams2.585","article-title":"Preventing thrombosis in a COVID-19 patient by combined therapy with nafamostat and heparin during extracorporeal membrane oxygenation","volume":"7","author":"Doi","year":"2020","journal-title":"Acute Med Surg"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/0306-3623(95)00072-0","article-title":"Mechanisms of hyperkalemia caused by nafamostat mesilate","volume":"26","author":"Muto","year":"1995","journal-title":"Gen Pharmacol Vasc Syst"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/1744-9987.13545","article-title":"Nafamostat mesilate inhibits linezolid metabolism via its antioxidant effects","volume":"24","author":"Kuriyama","year":"2020","journal-title":"Ther Apher Dial"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1840332\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:05:19Z","timestamp":1784095519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1840332\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":22,"alternative-id":["10.3389\/fmed.2026.1840332"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1840332","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1840332"}}